BMN 290
/ BioMarin
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 25, 2019
BioMarin announces first quarter 2019 financial results
(Biomarin Press Release)
- "The Company is currently conducting additional pre-clinical work on BMN 290 and will decide in the first half of 2019 whether to file an IND based on the outcome of those data."
IND • Preclinical
February 21, 2019
BioMarin announces full year and fourth quarter 2018 results
(PRNewswire)
- "BMN 290 is a selective chromatin modulation therapy intended for the treatment of Friedreich's ataxia...The Company is currently conducting additional pre-clinical work on BMN 290 and will decide in the first half of 2019 whether to file an IND based on the outcome of those data."
IND • Preclinical
1 to 2
Of
2
Go to page
1